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An expanded role for heterozygous 
mutations of ABCB4, ABCB11, 
ATP8B1, ABCC2 and TJP2 in 
intrahepatic cholestasis of 
pregnancy
Peter H. Dixon1, Melissa Sambrotta2, Jennifer Chambers1, Pamela Taylor-Harris1, Argyro 
Syngelaki3, Kypros Nicolaides3, A. S. Knisely4,5, Richard J. Thompson2 & Catherine 
Williamson1
Intrahepatic cholestasis of pregnancy (ICP) affects 1/140 UK pregnancies; with pruritus, hepatic 
impairment and elevated serum bile acids. Severe disease is complicated by spontaneous preterm 
delivery and stillbirth. Previous studies have reported mutations in hepatocellular transporters (ABCB4, 
ABCB11). High throughput sequencing in 147 patients was performed in the transporters ABCB4, 
ABCB11, ATP8B1, ABCC2 and tight junction protein 2 (TJP2). Twenty-six potentially damaging variants 
were identified with the following predicted protein changes: Twelve ABCB4 mutations - Arg47Gln, 
Met113Val, Glu161Gly, Thr175Ala, Glu528Glyfs*6, Arg590Gln, Ala601Ser, Glu884Ter, Gly722Ala, 
Tyr775Met (x2), Trp854Ter. Four potential ABCB11 mutations - Glu297Gly (x3) and a donor splice site 
mutation (intron 19). Five potential ATP8B1 mutations - Asn45Thr (x3), and two others, Glu114Gln and 
Lys203Glu. Two ABCC2 mutations - Glu1352Ala and a duplication (exons 24 and 25). Three potential 
mutations were identified in TJP2; Thr62Met (x2) and Thr626Ser. No patient harboured more than one 
mutation. All were heterozygous. An additional 545 cases were screened for the potential recurrent 
mutations of ATP8B1 (Asn45Thr) and TJP2 (Thr62Met) identifying three further occurrences of 
Asn45Thr. This study has expanded known mutations in ABCB4 and ABCB11 and identified roles in ICP 
for mutations in ATP8B1 and ABCC2. Possible novel mutations in TJP2 were also discovered.
Intrahepatic cholestasis of pregnancy (ICP), also called obstetric cholestasis, is the commonest pregnancy-specific 
liver disease. Typically presenting in the third trimester, ICP can be debilitating for the mother and threaten 
the health of the fetus1–3. Affected women have abnormal values of hepatobiliary-injury biomarkers, including 
raised serum bile acid (BA) concentrations4, that typically resolve by 12 weeks postpartum. Adverse pregnancy 
outcomes occur more commonly when maternal serum bile acid concentrations are >40 µmol/L. They include 
spontaneous preterm labour, prolonged admission to the neonatal intensive care unit and third trimester intrau-
terine death2,3,5,6. ICP is associated with a disrupted metabolic profile7,8 and can have long-term consequences for 
the health of the mother9,10 and child11.
The aetiology of ICP is complex and not fully understood, but a role has been established for the effect of 
elevated reproductive hormones towards the end of pregnancy (estrogens and sulphated progesterone metabo-
lites), when the disease most commonly presents (12,13, reviewed in ref.14). Indications of genetic involvement in 
disease susceptibility are clear (reviewed in ref.15). Pedigree studies have identified families where ICP is inherited 
in an autosomal dominant sex-limited fashion16,17. The varying geographical prevalence also indicates genetic 
involvement, with population-specific genetic backgrounds conferring different levels of risk18. Historically the 
1Division of Women’s Health, King’s College London, London, UK. 2Division of Transplantation Immunology & 
Mucosal Biology, Liver Sciences, King’s College London, London, UK. 3Harris Birthright Centre for Fetal Medicine, 
King’s College Hospital, London, UK. 4Institute of Liver Studies, King’s College Hospital, London, UK. 5Present 
address: Institut für Pathologie, Medizinische Universität Graz, Graz, Austria. Correspondence and requests for 
materials should be addressed to C.W. (email: catherine.williamson@kcl.ac.uk)
Received: 30 June 2017
Accepted: 24 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIenTIFIC REPORTS | 7: 11823  | DOI:10.1038/s41598-017-11626-x
prevalence of ICP was highest amongst the Native Chilean population19. Further evidence of genetic involvement 
comes from sibling studies that show a 12-fold increase in risk between parous sisters20,21.
Severe childhood liver disease can be caused by homozygous mutations in genes that encode transporters 
involved in bile formation at the hepatocyte canalicular membrane. These transporters play roles in cholestatic 
disorders that range in severity from progressive paediatric disease to transient cholestasis associated with drug 
ingestion or pregnancy (ICP)22.
Studies of the gene ABCB4, (ATP binding cassette subfamily B member 4) encoding the phosphotidylcho-
line floppase MDR3 and homozygously mutated in progressive familial intrahepatic cholestasis (PFIC) type 3, 
identified a heterozygous mutation of ABCB4 first in a familial case23 and then in a sporadic instance of ICP24. 
Subsequent studies have identified a wide range of mutations of ABCB4 in ICP, most commonly missense muta-
tions15. Approximately 10% of women with ICP harbour a mutated allele of ABCB415. Mutations of ABCB4 have 
also been implicated in drug-induced cholestasis25 and low phospholipid-associated cholelithiasis26.
The bile salt export pump (BSEP), encoded by the gene ABCB11, (ATP binding cassette subfamily B mem-
ber 11) is homozygously mutated in PFIC type 2 and benign recurrent intrahepatic cholestasis (BRIC) type 227. 
Several studies found ABCB11 mutations in women affected with ICP28–30.
Of note is that in addition to causative mutations of ABCB4 and ABCB11 acting as Mendelian-like alleles, 
population studies of ICP cohorts have identified common genetic variants at these loci that contribute to disease 
risk, albeit to a much smaller degree than causative mutations31.
The third PFIC (and BRIC) gene, ATP8B1, (ATPase class 8B member 1) encoding a phosphatidyl serine flip-
pase (familial intrahepatic cholestasis 1, FIC1), has only been studied to a limited extent (with respect to sequenc-
ing) in ICP cohorts, and hence the role of genetic variation at this locus in ICP is not established32,33. A functional 
interdependence of this flippase with MDR3 in hepatocytes suggests that ATP8B1 remains a viable candidate for 
involvement in ICP susceptibility34, as does the link to ABCB11 function through FXR/PLD2 signalling35.
Another canalicular ATP-driven transporter, the multidrug resistance-associated protein 2 (MRP2, encoded 
by the gene ABCC2(ATP binding cassette subfamily C member 2) is involved in bile formation. This protein 
exports bilirubin, some bile acids and many other anion conjugates into bile. Homozygous mutations of ABCC2 
cause the rare liver disorder Dubin-Johnson syndrome, which presents with conjugated hyperbilirubinaemia36. 
Although common variation and ICP susceptibility have been investigated at this locus in population cohorts, 
with conflicting results31,37,38, there are no published analyses of comprehensive sequencing of the coding region 
of ABCC2 in an ICP cohort.
Familial forms of severe progressive cholestasis without a confirmed genetic diagnosis also exist39. Mutations 
of another gene, tight junction protein 2 (TJP2) have recently been implicated in some patients with such dis-
ease40. The encoded protein named zona occludens 2 (ZO-2) is a cytosolic component of a number of types of 
cell-cell junctions at many sites, interacting with membrane proteins and cytoskeletal proteins. The detergent 
actions of bile acids in the liver on mutated cellular junctions are postulated to cause the cholestatic phenotype40. 
To date this gene has not been studied in ICP. Given the role of other PFIC genes in ICP, TJP2 seems a reasonable 
candidate for analysis.
To clarify the extent of involvement in ICP of these genes implicated in familial cholestasis we undertook 
high-throughput targeted sequencing of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in a cohort of 147 women 
with ICP.
Patients. The study included 147 women with a confirmed diagnosis of ICP, recruited through the Women’s 
Health Research Centre at Queen Charlotte’s and Chelsea Hospital, Imperial College Healthcare NHS trust, St. 
Mary’s Hospital Imperial College London, and North Lincolnshire and Goole Hospitals NHS foundation trust. 
All patients provided written informed consent, conforming to the 1975 Helsinki guidelines; permission for 
the study was granted by the ethics committee of the Hammersmith Hospitals NHS Trust, London (references 
REC97/5197 and 08/H0707/21).
ICP was diagnosed as described previously on the basis of clinical symptoms (pruritus without identifiable 
skin lesions other than excoriations) and routine laboratory investigations33. ICP was confirmed with detection 
of raised maternal serum bile acids. Women were excluded if viral or autoimmune hepatobiliary disease was 
diagnosed. A larger cohort of 545 patients with ICP, described in a previous study31, was used to evaluate potential 
recurrent mutations.
Results
Genes implicated in familial cholestasis underwent targeted next-generation sequencing using the MiSeq plat-
form in a cohort of 147 ICP patients. This identified 26 potentially pathogenic variations. Table 1 shows each 
variant identified together with its predicted protein consequence. Clinical findings for each patient in whom a 
potential mutation was identified are also shown (Table 2). All of the described mutations were observed in the 
heterozygous state and no patient harboured more than one potentially pathogenic variant. The frequency of two 
of the previously identified common susceptibility variants for ICP31; namely rs2109505 in ABCB4 and rs2287622 
in ABCB11, was noted in these individuals (Table 1). All of the missense variants identified, except where speci-
fied (Table 1) were predicted to be pathogenic by SIFT and MutationTaster.
ABCB4 variants. Consistent with previous findings15, the largest number of potential mutations (11 dif-
ferent variants in 12 patients) were identified in the gene encoding the phosphatidyl choline floppase ABCB4 
in this patient cohort (Table 1). Two predicted resulting variants, namely Thr175Ala and Arg590Gln, have pre-
viously been reported as pathogenic in cholestatic disease41,42. Three novel mutations are predicted to result in 
a frameshift leading to a stop codon six missense amino acids thereafter (Glu528Glyfs*6) and two immediate 
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introductions of a premature stop codon (Glu684Ter, Trp854Ter), a type of mutation only very infrequently pre-
viously described in ICP15. The remaining 7 mutations are novel missense changes predicted to be pathogenic 
(Alamut).
ABCB11 variants. Fewer potentially pathogenic variants (n = 2, 4 patients) were identified in ABCB11, 
encoding the bile salt export pump. A recurrent mutation, predicted to yield the substitution Glu297Gly, first 
described in PFIC2 patients27, and later identified in a study of ICP patients29, was discovered in 3 separate 
patients not known to be related. A donor splice site mutation in intron 19 was identified with the predicted 
consequence of an exon skipping event. A missense variation, resulting in the protein change Asn591Ser (dbSNP: 
rs11568367), was identified in an additional patient, which has previously been reported in ICP28. However, 
despite this amino acid being highly conserved, bioinformatic tools predict the variation to be benign; this allele 
is also relatively common in the South Asian population (MAF 11%). Thus, it seems not likely to be a pathogenic 
variant.
ATP8B1 variants. Several variants of interest were identified in ATP8B1, encoding a phosphatidyl ser-
ine flippase. A mutation predicted to be pathogenic by SIFT and Mutation Taster, causing the protein change 
Asn45Thr, was seen in 3 unrelated individuals. Two further variants predicted to be pathogenic were identified in 
2 additional patients, resulting in the protein changes Glu114Gln and Lys203Glu. To clarify the potential patho-
genic and recurrent role (in ICP) of the Asn45Thr variant a cohort of 545 cases was screened for this change (see 
methods above); an additional 3 patients harbouring this variant were identified (Tables 1 and 2).
ABCC2 variants. Two significant alterations were identified in ABCC2, encoding MRP2, a transporter of 
conjugated bilirubin and other organic anions. A single missense substitution, predicted to result in the protein 
change Glu1352Ala was identified in one patient. Alamut analysis indicated that SIFT and mutationTaster both 
predict the change to be deleterious. A second identified DNA change, confirmed by RT-PCR dosage method-
ology, was a genomic duplication of 5299 base pairs, encompassing exons 24 and 25 of the gene and predicted 
Patient DNA Change
Predicted Protein 
Change
Prediction 
pathogenic? Database ref rs2287622 rs2109505
ABCB4
1 c.140G > A p.Arg47Gln y rs372685632 VA AT
2 c.337A > G p.Met113Val y rs757245592 VA AA
3 c.482A > G p.Glu161Gly y NV VA AT
4 c.523A > G p.Thr175Ala y rs58238559 VA AA
5 c.1583delA p.glu528glyfs*6 y NV VA TT
6 c.1769G > A p.Arg590Gln y rs45575636 VV AT
7 c.1801G > T p.Ala601Ser y NV AA AA
8 c.2050G > T p.Glu684Ter y NV VV AA
9 c.2165G > C p.Gly722Ala y rs779885518 VV AT
10 c.2324C > T p.Tyr775Met y rs148052192 VA AA
11 c.2324C > T p.Tyr775Met y rs148052192 AA AA
12 c.2561G > A p.Trp854Ter y NV VV AA
ABCB11
13 c.890A > G p.Glu297Gly y rs11568372 AA AA
14 c.890A > G p.Glu297Gly y rs11568372 VA AA
15 c.890A > G p.Glu297Gly y rs11568372 AA AT
16 c.2343 + 1G > T Intron 19 splice y rs774411820 AA AA
ATP8B1
17 c.134A > C p.Asn45Thr y rs146599962 AA AA
18 c.134A > C p.Asn45Thr y rs146599962 VV AA
19 c.134A > C p.Asn45Thr y rs146599962 VA AA
20 c.340G > C p.Glu114Gln y rs753142591 VA AT
21 c.607A > G p.Lys203Glu y rs56355310 VA AT
27 c.134A > C p.Asn45Thr y rs146599962 NT NT
28 c.134A > C p.Asn45Thr y rs146599962 NT NT
29 c.134A > C p.Asn45Thr y rs146599962 NT NT
ABCC2
22 c.4055A > C p.Glu1352Ala y NV AA AT
23 dupl. ex 24–25 ins then Ter 1 esv3423829 AA AA
TJP2
24 c.185C > T p.Thr62Met y/n 2 rs138241615 AA AA
25 c.185C > T p.Thr62Met y/n 2 rs138241615 VA AA
26 c.1877C > G p.Thr626Ser y/n 2 rs149911553 AA AA
Table 1. Potential pathogenic variants identified in this study. Notes: Individuals in italics were identified by 
second screen of larger cohort. NV - novel variant not currently reported in dbSNP. NT - not typed. 1 Insertion 
is out of frame. 2 SIFT predicts tolerated, mutation taster predicts disease causing. rs2287622 shows amino acids 
at this SNP, rs2109505 is nucleotides (SNP is synonymous).
www.nature.com/scientificreports/
4SCIenTIFIC REPORTS | 7: 11823  | DOI:10.1038/s41598-017-11626-x
to result in the insertion of a premature stop codon. This copy number variant has been reported once before 
(database reference esv3423829).
TJP2 variants. Three patients harboured TJP2 variants of potential interest. Two unrelated individuals had 
the same DNA mutation causing the protein change Thr62Met. This alteration is predicted to be disease causing 
by Mutation Taster; SIFT, however, predicts this change to be tolerated. A second missense alteration seen in one 
patient is predicted to cause the protein alteration Thr626Ser. This change is also assessed as tolerated by SIFT 
but as disease causing by Mutation Taster. 545 ICP cases (as above) were subsequently screened for the possible 
recurrent Thr62Met variant, however no further ICP cases carrying this change were identified.
Biochemical and clinical features of ICP cases with variants. Elevations in serum BA and alanine 
transaminase (ALT) activity values varied among patients and there was no particular trend for greater elevation 
of specific analytes in women with particular mutations in specific genes. Hyperbilirubinaemia was rare. It did, 
however, occur in association with ABCB4, ABCB11 or ATP8B1 variants. Six women had elevated bilirubin values 
(>20 µmol/L); all had severe ICP (serum BA > 40 µmol/L). The two whose bilirubin concentrations were consist-
ent with jaundice (>35 µmol/L) harboured ABCB4 mutations. Only two women with mutations (one in ABCB4, 
one in ATP8B1) were known to have elevated gamma glutamyl transferase (GGT) levels. Of the 26 women with a 
mutation in a biliary transporter (ABCB4, ABCB11, APT8B1, ABCC2), 12 (46%) had an established family history 
of biliary disease (ICP, cirrhosis or gallstones).
Patient ALT ALP GGT Bilirubin
Bile 
Acids
Maternal 
Biliary 
Disease
F/H 
Biliary 
Disease
Adverse 
pregnancy 
outcomes
ABCB4
1 345 159 20 40 150 no no SPL, M
2 27 204 13 4 16 no no PPH
3 45 280 18 12 39 no no no
4 35 284 NP 6 30 no no no
5 172 522 20 13 239 G G, ICP no
6 291 244 18 8 39 G G no
7 1802 710 10 18 108 no ICP* M, FHR
8 58 261 NP NP 78 no G no
9 579 270 NP NP 112 G G M, FHR
10 115 376 28 7 44 no Cirr no
11 776 292 NP 57 50 G, C G, ICP FHR
12 803 204 66 NP 222 no G, Cirr no
ABCB11
13 229 238 NP 23 118 G, C nk SPL, M, FHR
14 94 190 12 8 23 no no no
15 NP 91 8 4 14 no no no
16 32 302 11 4 44 G no NNU
ATP8B1
17 410 344 29 16 27 no no PPH
18 131 247 38 26 69 no no no
19 707 263 17 20 120 G G FHR
20 23 227 36 10 35 G G, Cirr no
21 96 261 33 9 22 no no no
27 506 510 110 16 182 no G SPL
28 415 358 32 18 16 nk nk no
29 101 323 18 4 17 no no FHR
ABCC2
22 14 291 23 11 66 no no no
23 80 257 NP 10 73 no G no
TJP2
24 110 178 NP 9 57 nk nk no
25 225 435 26 17 42 no no SB
26 740 527 NP NP 127 no no no
Table 2. Clinical and biochemical findings in the individuals with potential mutations. Individual in 
italics identified by second screen of larger cohort. NP – not performed. G – gallstones. PPH - post partum 
haemorrage. ALT - alanine transaminase. C - oral contraceptive induced cholestasis. SPL - spontaneous preterm 
labour (<37 weeks). ALP - alkaline phosphatase. ICP - intrahepatic cholestasis of pregnancy. SB - still birth in 
previous pregnancy. GGT - gamma glutamyl transferase. Cirr - liver cirrhosis. M - mecconium staining. F/H - 
family history. FHR - fetal heart rate abnormalities. nk - not known. NNU - > 48 hr admission to neonatal unit. 
*- based on recollection of maternal aunt.
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Discussion
This study is the largest analysis to date of the role of mutations of familial cholestasis genes in ICP susceptibility. 
Previous studies have identified genetic contributions to the disease primarily focussing on ABCB4. Here, by 
using a next generation sequencing approach, a panel of genes could be analysed in parallel in a large cohort of 
patients.
Our analysis identified a number of mutations of ABCB4, encoding the phosphatidyl choline floppase MDR3. 
ABCB4 has been analysed in a number of ICP cohorts and mutations in this gene represent the largest overall 
genetic contribution to ICP susceptibility known to date15. Several groups have established functional assays for 
this protein that can incorporate mutant constructs43–46. Such assays help to define the impact of a given variant 
on protein function; bioinformatics predictors of clinical importance of variants like those used in this study 
are useful (and improving) but can never be conclusive. Functional assays are being used to classify mutations 
by mechanism of effect on protein function (e.g., trafficking defect resulting in mis-localisation, loss of floppase 
activity). This is of value in ABCB4-associated diseases; these data may predict response to therapy intended to 
rescue floppase function. It is noteworthy that in the ABCB4 mutant carrier group, 8/12 (67%) had a family his-
tory of biliary disease (ICP, cholelithiasis or cirrhosis) (Table 2). This is consistent with a study of parous women 
with LPAC and co-existing ABCB4 mutations, in which approximately 50% developed ICP when pregnant47.
A clear role is now established for genetic variation in ABCB11 contributing to the aetiology of ICP, although 
one seemingly less than that of ABCB4. Our study has confirmed this role; taken together with other data, it sug-
gests that up to 5% of ICP cases harbour a heterozygous mutation of ABCB1128–30. In particular, the two mutant 
alleles found commonly in the PFIC2/BRIC2 population (Glu297Gly and Asp482Gly) are also present in the ICP 
population. Functional studies of ABCB11 mutations have been performed in addition to mini-gene construct 
splicing analysis and immunohistochemical studies to establish genotype/phenotype correlations48–50; studies of 
this type are helpful to clarify the clinical relevance of findings of unknown significance. Two of the five women in 
this group had cholelithiasis (Table 2). Previous studies of ICP patients and ABCB11 mutations have not identified 
this association.
Analysis of ATP8B1 in ICP has been limited, with the largest study focussing on common SNPs and popula-
tion risk rather than mutations [31–33]. In this study we confirmed a small potential role for ATP8B1 variants to 
contribute to ICP. We examined a larger ICP population for the recurrent variant (Asn45Thr) and identified three 
further individuals harbouring it. Taken with the other mutations identified in this gene, it is therefore possible 
that up to 3% of ICP patients may have a heterozygous mutation of ATP8B1. However, the Asn45Thr variant, 
although predicted to be deleterious, is fairly common in the normal population (global minor allele frequency 
0.49%), and has been reported in a study of chronic pancreatitis51. Although this does not exclude this variant 
from having a mildly deleterious effect on protein function, in vitro experimental approaches are warranted to 
confirm if this variant contributes to disease risk.
That our cohort included two patients with potentially pathogenic variants of ABCC2, a missense mutation 
predicted to be pathogenic and a large in-frame duplication, is of interest. No published studies report sequencing 
this gene in ICP; our data suggest a small but potentially overlooked contribution to ICP by heterozygous ABCC2 
mutations.
This study is the first to examine TJP2 in an ICP cohort. We have identified some evidence for involvement of 
this gene, with three occurrences of variants that may predispose to disease. However, as bioinformatics predic-
tion tools did not agree on the clinical relevance of these changes, further analysis is warranted. Development of 
functional assays for this protein, together with further sequencing of TJP2 in larger patient cohorts, will be key 
to understanding the role of these variants.
A spectrum of variants have been identified in this and other ICP cohorts. Although some variants will be 
predicted to have only a mild impact upon disease susceptibility, either from database predictions or using in 
vitro assays, the cholestatic impact of gestational elevations of reproductive hormones may result in a more severe 
phenotype in the context of pregnancy.
Heterozygous mutations in the five genes sequenced were identified in nearly 20% of the ICP population being 
studied. However, the mutant-carrying groups exhibited no clear phenotypic differences (Table 2). Serum BA or 
ALT values did not vary by gene and raised serum GGT activity was not common in those with a mutation in 
ABCB4. Biomarkers that indicate which biliary transporter is mutated in a specific ICP patient thus remain to 
be found. That >50% of the women with identified variants had a family history of biliary disease is notewor-
thy; this information could be useful in a clinical setting to make decisions about mutation screening. Further 
studies with deeper phenotyping approaches (especially metabolic profiling/serum lipidomics and reproductive 
hormone metabolite analysis, based on our knowledge of disease pathophysiology) are warranted to determine if 
these mutation groups can be distinguished by clinical phenotype. Research into the impact of specific genotypes 
on drug response, risk of subsequent hepatobiliary disease, resolution of symptoms after delivery, duration of 
symptoms, and long term maternal and child health will be of particular value.
In this study, we used a candidate sequencing approach to identify mutations with a potentially large impact 
on protein function. Separate studies have also taken a population genetics approach using candidate single 
nucleotide polymorphisms and/or tagging SNPs in an attempt to identify common variants that contribute to 
overall risk31,38,52,53. Common variants that make a much smaller contribution to disease risk in ICP populations 
have been identified at the ABCB4 and ABCB11 loci (in particular rs2109505 (ABCB4) and rs2287622/rs7577650 
(ABCB11)28,31,53). Thus, the genetic architecture of ICP is complex, with rare mutant alleles, often but not exclu-
sively specific to each patient, present in affected women, such as reported in this study, together with common 
variants at the same loci that represent risk alleles as we have previously described. Although our previous study 
excluded a large role for common variation of ATP8B1 and ABCC2 in ICP31, studies in larger cohorts may iden-
tify variants conferring a small degree of risk (or protection), given the potential high-impact mutations of these 
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genes identified by this study. Common variation around TJP2 causing small alterations in risk (which this study 
was not powered to detect) may also play a role.
We have previously studied the role of FXR variants in ICP and identified a small number of rare variants with 
a functional effect54. When designing this study this gene was not included in the screening panel. However, the 
recent identification of FXR mutations in progressive familial intrahepatic cholestasis strengthen the case for 
further FXR analysis in future studies of ICP55.
The catalogue of ICP-associated mutations that this analysis, and others, have established permits considera-
tion of the possibility of precision genomic medicine. With sequencing costs falling and technology continuing 
to advance, to contemplate screening all of the candidate genes for ICP is now feasible, enabling genetic diagnosis 
that in future may allow better targeted treatment and surveillance.
Methods
Blood samples were collected in standard EDTA vacutainers and buffy coats were prepared by centrifugation 
using standard protocols. DNA was extracted from 200 µl of buffy coat using the Qiagen Blood mini kit (Crawley, 
UK). Extracted DNA was assessed for purity using an ND-1000 Nanodrop spectrophotometer (Thermofisher 
Scientific, Loughborough, UK) and quantified using a Qubit fluorimeter (Thermofisher).
Selected genes known or hypothesized to be involved in ICP (ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2) 
underwent targeted next-generation sequencing. Oligonucleotides (“oligos”) to screen the entire coding region 
of each gene were designed using the Illumina web-based sequencing assay design tool Design Studio (http://
designstudio.illumina.com/) and used in the Illumina TruSeq custom amplicon v1.5 workflow according to the 
manufacturer’s instructions. This workflow has three main stages: 1) hybridisation of the oligos to 50 ng/µl of 
genomic DNA; 2) extension and ligation of the oligos; 3) PCR amplification using two unique index primers 
for sample. Afterwards, sample DNA concentrations were normalised using the Illumina bead-based system 
and pooled in a final library. The pooled library was then sequenced using a MiSeq Reagent Kit v2, 300-cycle 
(2 × 150bp), on the MiSeq benchtop sequencing platform (Illumina, Cambridge, UK).
Sequencing data were analysed using a bioinformatics pipeline designed in Biomedical Genomic Workbench 
2.5.1 (CLC bio, Aarhus, Denmark). Sequence reads were mapped against the human reference (hg19/GRCh37). 
Variants were called when they had a minimum coverage of 20× and a probability of 80% of being different from 
the reference, in accordance with the Bayesian model incorporated into the software. Putative variants identified 
were filtered according to the quality and the frequency of occurrence; all changes having an allele read frequency 
of less than 10% and an average base quality (Phred score) of less than 20 were removed. The variants identified 
were further annotated using dbSNP v139 and the 1000 Genome Project database. A deeper investigation was 
also performed using Alamut Visual 2.7.1 (Interactive Biosoftware, Rouen, France), in which each variant was 
integrated with allele frequency information derived from several single nucleotide polymorphism (SNP) data-
bases, including dbSNP v144, the 1000 Genomes Project, the Exome Aggregation Consortium and the National 
Heart Lung and Blood Institute Grand Opportunity Exome Sequencing Project and with in silico missense pre-
dictions from SIFT (sorting intolerant from tolerant) and MutationTaster. Copy number variants (CNVs) were 
detected via in-house dosage analysis using the read-counts generated by the NGS analysis. The CNVs were 
confirmed by RT-PCR using Universal Probe Library (Roche).
Each potential pathogenic variant was confirmed in patient samples using routine Sanger sequencing. 
Forward and reverse primers were manually designed for the flanking regions and purchased from Integrated 
DNA Technologies (sequences available on request).
Analysis of potential recurrent mutations of ATP8B1 and TJP2 were performed following primer design 
(“Primer picker”, LGC Genomics, Hoddesdon, UK) using a competitive allele specific PCR SNP system using 
fluorescence resonance energy transfer (FRET) quencher cassette oligonucleotides (KASPTM, LGC Genomics).
Data Availability. Any further information on the sequencing data described in this paper is available from 
the corresponding author on reasonable request.
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